NO20043900L - Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner - Google Patents

Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner

Info

Publication number
NO20043900L
NO20043900L NO20043900A NO20043900A NO20043900L NO 20043900 L NO20043900 L NO 20043900L NO 20043900 A NO20043900 A NO 20043900A NO 20043900 A NO20043900 A NO 20043900A NO 20043900 L NO20043900 L NO 20043900L
Authority
NO
Norway
Prior art keywords
integrins
compounds
sub
leukocyte adhesion
adhesion mediated
Prior art date
Application number
NO20043900A
Other languages
English (en)
Other versions
NO329933B1 (no
Inventor
Eugene D Thorsett
Michael A Pleiss
Christopher M Semko
Andrei W Konradi
Ying-Zi Xu
Frank Stappenbeck
Brian P Stupi
Jenifer Smith
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO20043900L publication Critical patent/NO20043900L/no
Publication of NO329933B1 publication Critical patent/NO329933B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043900A 2002-05-24 2004-09-17 Heterocykliske forbindelser, farmasoytiske sammensetninger samt anvendelser derav NO329933B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38302002P 2002-05-24 2002-05-24
PCT/US2003/016804 WO2003099809A1 (en) 2002-05-24 2003-05-27 HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY α4 INTEGRINS

Publications (2)

Publication Number Publication Date
NO20043900L true NO20043900L (no) 2004-11-10
NO329933B1 NO329933B1 (no) 2011-01-24

Family

ID=29584493

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043900A NO329933B1 (no) 2002-05-24 2004-09-17 Heterocykliske forbindelser, farmasoytiske sammensetninger samt anvendelser derav

Country Status (23)

Country Link
US (3) US7135477B2 (no)
EP (1) EP1507775B1 (no)
JP (1) JP4469715B2 (no)
KR (1) KR100978832B1 (no)
CN (1) CN1314682C (no)
AT (1) ATE419243T1 (no)
AU (1) AU2003240823C1 (no)
BR (1) BR0308881A (no)
CA (1) CA2481926C (no)
DE (1) DE60325583D1 (no)
DK (1) DK1507775T3 (no)
EA (1) EA008256B1 (no)
EC (1) ECSP045425A (no)
ES (1) ES2320436T3 (no)
HK (1) HK1072608A1 (no)
IL (2) IL164225A0 (no)
MX (1) MXPA04010995A (no)
NO (1) NO329933B1 (no)
NZ (1) NZ535504A (no)
TW (1) TWI281470B (no)
UA (1) UA76339C2 (no)
WO (1) WO2003099809A1 (no)
ZA (1) ZA200407590B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359115C (en) * 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
NZ544367A (en) * 2003-06-25 2009-12-24 Elan Pharm Inc Combination therapy involving methotrexate for treating rheumatoid arthritis
WO2005111020A2 (en) * 2004-04-30 2005-11-24 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
EP2258399A3 (en) * 2004-07-08 2011-08-10 Elan Pharmaceuticals Inc. Multivalent VLA-4 antagonists comprising polymer moieties
MX2007014267A (es) * 2005-05-20 2008-02-07 Elan Pharm Inc Derivados de imidazolona fenilamina como antagonistas vla-4.
NZ567270A (en) 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
NZ570679A (en) * 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
EP2007392A4 (en) 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
KR20080104343A (ko) * 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
JP2011506322A (ja) * 2007-12-07 2011-03-03 エラン ファーマシューティカルズ，インコーポレイテッド 液性腫瘍を治療するための方法および組成物
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
JP5514804B2 (ja) * 2008-04-29 2014-06-04 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
SG10201401836RA (en) * 2009-04-27 2014-10-30 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
ME03026B (me) 2010-01-11 2018-10-20 Biogen Ma Inc Test za antitijela protiv jc virusa
JP6080521B2 (ja) * 2012-11-30 2017-02-15 インターナショナル・ビジネス・マシーンズ・コーポレーションＩｎｔｅｒｎａｔｉｏｎａｌ Ｂｕｓｉｎｅｓｓ Ｍａｃｈｉｎｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 広域分散医療情報ネットワークのデータ管理機構
US10119976B2 (en) 2013-05-28 2018-11-06 Biogen Ma Inc. Method of assessing risk of PML
RU2729518C2 (ru) * 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
KR102652797B1 (ko) 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린의 억제를 위한 화합물
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
CN109541237A (zh) * 2018-12-28 2019-03-29 吴江近岸蛋白质科技有限公司 纤维连接蛋白的生物学活性测定方法
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4070457A (en) * 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) * 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4046876A (en) * 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073914A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) * 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055636A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5727454B2 (no) * 1975-02-21 1982-06-10
CA1102316A (en) 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US4036955A (en) * 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018913A (en) * 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) * 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) * 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) * 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4565814A (en) 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) * 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
US4595364A (en) * 1984-02-15 1986-06-17 Molten Corp. Dental prosthesis and process for preparing the same
PH22520A (en) * 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) * 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
DE3904931A1 (de) * 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) * 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) * 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) * 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
AU1354292A (en) 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
IT1247509B (it) * 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
RU2126794C1 (ru) * 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
DE4227748A1 (de) * 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
ATE237342T1 (de) 1994-07-11 2003-05-15 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
BR9610422A (pt) * 1995-08-30 1999-07-13 Searle & Co Derivados de meta-guanidina uréia tiouréia ou ácido aminobenzóico azacíclico como antagonistas de integrina
ES2155172T3 (es) * 1995-09-29 2001-05-01 Sankyo Co Derivados milbemicina 5-oxima 13-sustituidos, su preparacion y su uso contra insectos y otras plagas.
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
KR100459978B1 (ko) 1996-06-21 2005-01-15 다께다 케미칼 인더스트리즈,리미티드 펩티드제조방법
CZ424998A3 (cs) 1996-06-28 1999-03-17 Merck Patent Gmbh Deriváty fenylaminu jakožto integrinové inhibitory
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647317A1 (de) * 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
AU739035B2 (en) 1996-11-22 2001-10-04 Elan Pharmaceuticals, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
WO1998033783A1 (en) 1997-02-04 1998-08-06 Versicor, Inc. Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
BR9812114A (pt) 1997-07-31 2000-07-18 Elan Pharm Inc Compostos do tipo fenilalanina substituìda que inibem a adesão de leucócito mediada por vla-4
IL133641A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022406A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
DK1005446T3 (da) 1997-08-22 2004-06-07 Hoffmann La Roche N-aroylphenylalaninderivater
CN100369888C (zh) 1997-08-22 2008-02-20 霍夫曼-拉罗奇有限公司 芳酰基苯丙氨酸衍生物
CN1294576A (zh) 1998-01-23 2001-05-09 诺瓦提斯公司 Vla－4拮抗剂
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
BR9909626A (pt) 1998-04-16 2002-01-15 Texas Biotechnology Corp Compostos que inibem a ligação de integrina a seus receptores
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
AU2623900A (en) * 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
CA2359115C (en) * 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins

Also Published As

Publication number Publication date
CA2481926A1 (en) 2003-12-04
DK1507775T3 (da) 2009-05-11
EA008256B1 (ru) 2007-04-27
US7427628B2 (en) 2008-09-23
JP2005527628A (ja) 2005-09-15
ECSP045425A (es) 2005-03-10
DE60325583D1 (de) 2009-02-12
NO329933B1 (no) 2011-01-24
US7026328B2 (en) 2006-04-11
ZA200407590B (en) 2006-10-25
CN1314682C (zh) 2007-05-09
ES2320436T3 (es) 2009-05-22
EP1507775A1 (en) 2005-02-23
BR0308881A (pt) 2005-01-11
HK1072608A1 (en) 2005-09-02
US7135477B2 (en) 2006-11-14
US20050119290A1 (en) 2005-06-02
TW200400946A (en) 2004-01-16
US20070027131A1 (en) 2007-02-01
CA2481926C (en) 2012-04-24
AU2003240823A1 (en) 2003-12-12
KR20050003434A (ko) 2005-01-10
WO2003099809A1 (en) 2003-12-04
EP1507775B1 (en) 2008-12-31
KR100978832B1 (ko) 2010-08-30
ATE419243T1 (de) 2009-01-15
AU2003240823B2 (en) 2008-11-06
IL164225A0 (en) 2005-12-18
EA200401562A1 (ru) 2005-06-30
AU2003240823C1 (en) 2009-05-28
MXPA04010995A (es) 2005-09-08
CN1656090A (zh) 2005-08-17
TWI281470B (en) 2007-05-21
UA76339C2 (en) 2006-07-17
IL164225A (en) 2010-11-30
US20040138243A1 (en) 2004-07-15
EP1507775A4 (en) 2006-05-24
JP4469715B2 (ja) 2010-05-26
NZ535504A (en) 2005-11-25

Similar Documents

Publication Publication Date Title
NO20043900L (no) Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
DK1940826T3 (da) Pyrimidinylamidforbindelser, der inhiberer leukocytadhæsion medieret gennem BLA-4
MXPA01007335A (es) Derivados de acilo los cuales tratan trastornos relacionados con alfa4 beta1 integrina y cd49d/cd29 (vla-4).
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
NO20000451L (no) Forbindelser som inhiberer leukocyttadhesjon mediert av VLA-4
NO20000412L (no) Dipeptidforbindelser som inhiberer leukocytt-adhesjon mediert av VLA-4
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2005111020A3 (en) Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
DE60009883D1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7- rezeptor antagonisten
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees